A research team led by Dr Somnath Mukhopadhyay, Professor Brian Lipworth and Dr Colin Palmer, has found that a specific genetic variant, known as the Arg/Arg-16 variant, causes salmeterol to be ineffective.
Their research shows that while most patients on salmeterol have their asthma well controlled, those with the Arg/Arg-16 variant have almost double the number of asthma attacks compared to those with the other forms of this gene.
Future research will determine if genetic testing for the Arg/Arg 16 variant should be used in deciding routine asthma prescribing. This is a first step in the path to "personalized medicine" where genetic information will lead to the more effective use of drugs.
"It was apparent that some patients with asthma could be failing to respond to inhaled salmeterol, but we have identified a likely cause for this that is linked to this genetic status," said Dr Mukhopadhyay, of the Children’s Asthma and Allergy Research Unit at the University.
"Where this discovery takes us is towards more personalised asthma treatment, where we can identify which medicines can be used or avoided depending on an individual’s genetic profile and we can ensure the best possible treatment."
The Arg/Arg-16 variant genetic status is reasonably common and it is present in around 13% of young people with asthma in Tayside. The Dundee team studied 546 children and adolescents with asthma in Tayside.
The findings follow studies in America where the US Food and Drug Administration, the principal food and drug regulatory organisation in the United States, has previously warned in November 2005 that salmeterol was not effective in certain individuals, especially African Americans, although the genetic status of these individuals was not studied.
Salmeterol is part of a group of drugs known as beta-agonists, and is widely prescribed within the National Health Service to patients with asthma who fail to respond well to inhaled steroids.
There are 5.2 million people in the UK currently receiving various forms of asthma treatment, and an estimated 675,000 within this population carry the Arg/Arg-16 gene variation and therefore may not benefit from salmeterol treatment.
There are other drugs that can be used as alternative treatments in these individuals.
Although genetic testing is not performed through the NHS, it is important to note that the patients who are put on salmeterol should monitor if the medicine is working or not. If asthma is still poorly controlled on salmeterol, then alternatives, rather than additional treatments, may be more useful.
The results are published today by the leading chest medical journal Thorax, published by the British Thoracic Society and the BMJ Publishing Group.
Roddy Isles | alfa
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy